Welcome to our dedicated page for Vaso news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on Vaso stock.
Vaso Corporation reports developments for a diversified medical technology business spanning network and IT services, professional sales services for medical equipment, and proprietary medical products. Company updates commonly cover operating results by segment, deferred revenue trends, gross profit, expenses, and the effect of portfolio changes such as the sale of its healthcare IT business unit.
Recurring news also includes subsidiary activity. VasoHealthcare represents GE HealthCare diagnostic imaging and ultrasound products in certain U.S. market segments, while VasoMedical manages proprietary medical equipment and software and overseas assets, including China-based subsidiaries. Other updates address material agreements, shareholder meeting matters, and governance developments.
Vaso (OTCQX: VASO), a company focused on human capital, information technology, and MedTech sectors, has released a shareholder and employee letter on December 16, 2024. The letter outlines the company's achievements throughout the year and presents strategic developments and priorities for 2025. The communication covers operational developments, product updates, financial performance, and thought-leadership initiatives, with details available on the company's website.
Vaso (OTCQX: VASO) reported Q3 2024 financial results with revenue of $20.8 million, up 7% from $19.4 million in Q3 2023, driven by growth in network services. However, the company recorded an operating loss of $1.4 million compared to operating income of $907,000 in Q3 2023. The company maintains a strong balance sheet with $26.8 million in cash and investments, and generated $3.6 million in operating cash flow during the first nine months. Deferred revenue increased by $1.4 million to $33.1 million. The net loss for Q3 2024 was $1.2 million, compared to net income of $1.2 million in Q3 2023, primarily due to business combination costs of $1.5 million.
Vaso (OTCQX: VASO) has announced the termination of its Business Combination Agreement with Achari Ventures Holdings Corp. I. The company, based in Plainview, N.Y., made this decision on September 18, 2024. Vaso stated that it will continue to pursue opportunities to enhance stockholder value through various means, including:
- Internal growth
- New partnerships
- Strategic investments
The company's focus will remain on medical and IT service companies as it seeks to expand its business and create value for shareholders.
Vaso (OTCQX: VASO) has announced a change in the date of its special stockholders meeting. Originally scheduled for August 26, 2024, the meeting has been adjourned without considering any proposals. The new date is set for September 10, 2024, at 10:00 AM Eastern. The location remains the same: the Lever House at 390 Park Avenue, New York, NY 10022.
The company stated that this postponement, occurring after the Labor Day holiday, is intended to provide more stockholders with the opportunity to attend the meeting in person. This decision reflects Vaso's commitment to maximizing shareholder participation in important corporate decisions.
Vaso (OTCQX: VASO) reported its Q2 2024 financial results, with total revenue of $20.2 million, slightly down from $20.3 million in Q2 2023. The company's IT segment saw a 1% increase, while the professional sales service segment remained flat. The equipment segment experienced a 30% decrease. Gross profit decreased by 4% to $12.2 million. Net income for Q2 2024 was $1.2 million, down from $2.0 million in Q2 2023. Adjusted EBITDA was $1.2 million, compared to $2.1 million a year ago.
Despite lower earnings, Vaso maintains a strong financial position with $25.7 million in cash and cash equivalents. The company's deferred revenue stands at $31.7 million, with a multi-year high backlog of $39.4 million in the IT segment, indicating potential for future growth. Vaso is pursuing a NASDAQ listing through a proposed business combination with Achari Ventures Holdings Corp. I, with a special stockholders meeting scheduled for August 26, 2024.
Vaso (OTCQX: VASO) announced the SEC's approval of Achari Ventures Holdings Corp. I's (NASDAQ: AVHI) S-4 Registration Statement for their proposed business combination. Post-merger, the company will be renamed Vaso Holdings Corp. and listed on NASDAQ. Current Vaso stockholders will own 94-96% of the new entity, valued at approximately $176 million at closing.
Dr. Jun Ma, Vaso's President and CEO, highlighted the company's recent financial performance: annual revenues of $75.2M, $79.3M, and $81.0M in 2021, 2022, and 2023, respectively, with operating incomes of $2.5M, $6.5M, and $4.2M. The company has cash reserves of about $25 million. A special stockholders meeting is scheduled for August 26, 2024, to approve the business combination.
Vaso (OTCQX: VASO) announced its financial results for Q1 2024. Total revenue was $18.7 million, a 1.6% decrease year-over-year primarily due to lower equipment sales. Gross profit fell by 5.6% to $10.9 million, while SG&A expenses rose by 9.4% to $12.2 million. The company reported a net loss of $1.2 million and an adjusted EBITDA of negative $1.3 million. Despite these losses, Vaso's operating cash flow improved by $0.8 million year-over-year, and the company maintained a strong financial position with $26.0 million in cash and short-term investments as of May 3, 2024.
Summary not available.
Summary not available.
Summary not available.